REG - Diaceutics PLC - Diaceutics PLC - Strategic alliance with KPMG

DiaceuticsAnnouncement

14/02/2024 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240214:nRSN1443Da&default-theme=true

RNS Number : 1443D  Diaceutics PLC  14 February 2024

Diaceutics enters into strategic alliance with KPMG

 

Alliance will facilitate joint marketing of commercialisation solutions to
life science customers launching precision medicines

 

Combines Diaceutics' and KPMG's extensive data, expertise and reputation in
commercialising precision medicines with pharma and biotech customers

 

Belfast and London, 14 February 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to pharma and biotech customers is pleased
to announce a strategic alliance with KPMG LLP (KPMG), a global leader in tax,
audit and advisory services and commercialisation solutions for the healthcare
and life sciences industries. The goal of the alliance is to bring together
Diaceutics' leading technology solutions, which help pharma companies find
appropriate patients for their precision medicines, and KPMG's market-leading
advisory business. This strategic alliance will combine Diaceutics' and KPMG's
extensive knowledge, expertise and industry reputation, and build on their
significant individual successes in organically and inorganically transforming
precision medicine businesses and commercialising precision medicines over
multiple years.

Ryan Keeling, Diaceutics' Chief Executive Officer, commented:

 

'It is great to see this partnership come to life. We have worked alongside
KPMG leaders for many years with a strong admiration for their work in the
precision medicine space. This alliance formally recognises our common goals
and ambitions to collectively shape the future of precision medicine. Between
the two organisations we have worked on many of the precision medicine
therapies currently on market. This alliance will make it easier for the
world's largest and most innovative pharmaceutical and biotech organisations
to get access to the best expertise and the best data available."

 

Kristin Pothier, KPMG, Life Sciences Sector Leader and Global HCLS Deal
Advisory and Strategy Leader, commented:

 

"We look forward to formalising our long-standing collaboration with
Diaceutics with this strategic alliance and to the opportunity this presents.
Diaceutics' unrivalled data resource and industry expertise, combined with our
proprietary data, our global customer base and our experience across precision
medicine commercialisation and deal making, creates a strengthened capability
to help our clients commercialise precision medicine products and services
worldwide, and evolve the provision of healthcare."

Diaceutics is becoming the commercialisation partner of choice for pharma and
biotech companies launching precision medicines and counts 21 of the top 30
global pharma companies amongst its customers. KPMG is a market-leading and
globally recognised provider of tax, audit, and advisory services to the
world's leading healthcare and life sciences companies. Through its strategic
alliance partnerships, it has successfully built an ecosystem of the world's
leading technology brands, allowing KPMG to combine these alliances with its
expertise to bring transformative technologies to its clients.

The power of more efficient diagnostic pathways to improve treatment
outcomes is proven. These are, in turn, driving the shift to
precision medicine across the healthcare and life sciences ecosystem.
Diaceutics and KPMG believe there is a strategic opportunity to align their
advisory and data enabled commercialisation solutions to support this
ecosystem in harnessing the clinical and economic returns that precision
medicine can deliver.

This strategic alliance will identify opportunities to enable both Diaceutics
and KPMG to jointly market their commercialisation solutions to new and
existing customers, globally, and explore other areas of mutual benefit whilst
demonstrating their shared dedication to shaping the future of precision
medicine, and supporting our clients in bringing life changing medicines to
patients. Notably, both management teams have independently played pivotal
roles in the launch of the majority of significant companion diagnostics and
their associated therapeutics to have come to market.

The collaborative expertise of both KPMG and Diaceutics positions them at the
forefront of advancing the industry's capabilities in the evolving landscape
of healthcare decisions, driven through real-world data insights.

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance
with the Company's obligations under Article 17 of MAR. The person responsible
for making this announcement on behalf of the Company is Nick Roberts, Chief
Financial Officer.

 

Enquiries:

 

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                                                    Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                                                    investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)                                          Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                                                            Tel: +44(0)20 3405 0205
 Caroline Forde                                                                           diaceutics@almastrategic.com
 Kinvara Verdon

 KPMG LLP

 Kristin Pothier, Life Sciences Sector                                                    us-hclspractice@kpmg.com
 Leader
 Alasdair Milton, Principal, KPMG Life Sciences Strategy

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®

 

About KPMG

KPMG LLP is one of the largest providers of professional services-advisory,
strategy, audit, and tax- to the healthcare and life sciences industry
globally with more than 4,200 healthcare and life sciences industry-specific
partners and professionals. Our precision medicine expertise spans the globe
and helps provide strategic and tactical solutions devoted to the future of
medicine. For more information: Precision Medicine (kpmg.us)
(https://advisory.kpmg.us/articles/2023/precision-medicine.html)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALLTIMTTMTBBBJI